Lakefront Biotherapeutics/€LKFT
05:30
03:10
00:45
22:25
20:00
1D1W1MYTD1Y5YMAX
About Lakefront Biotherapeutics
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€LKFT
Sector
Primary listing
AEX
Employees
704
Headquarters
Website
LKFT Metrics
BasicAdvanced
€1.5bn
3.16
€7.42
-
-
Price and volume
Market cap
€1.5bn
52-week high
€32.64
52-week low
€22.24
Average daily volume
1.1k
Financial strength
Current ratio
30.478
Quick ratio
30.235
Long term debt to equity
0.149
Total debt to equity
0.198
Interest coverage (TTM)
1,611.98%
Profitability
EBITDA (TTM)
662.957
Gross margin (TTM)
53.99%
Net profit margin (TTM)
46.83%
Operating margin (TTM)
60.39%
Effective tax rate (TTM)
-3.55%
Revenue per employee (TTM)
€1,480,000
Management effectiveness
Return on assets (TTM)
10.65%
Return on equity (TTM)
16.26%
Valuation
Price to earnings (TTM)
3.155
Price to revenue (TTM)
1.478
Price to book
0.47
Price to tangible book (TTM)
0.47
Price to free cash flow (TTM)
-4.97
Free cash flow yield (TTM)
-20.12%
Free cash flow per share (TTM)
-4.709
Growth
Revenue change (TTM)
262.17%
Earnings per share change (TTM)
-388.18%
3-year revenue growth (CAGR)
85.52%
10-year revenue growth (CAGR)
34.13%
3-year earnings per share growth (CAGR)
38.90%
10-year earnings per share growth (CAGR)
15.59%
What the Analysts think about LKFT
Analyst ratings (Buy, Hold, Sell) for Lakefront Biotherapeutics stock.
LKFT Financial Performance
Revenues and expenses
LKFT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lakefront Biotherapeutics stock?
Lakefront Biotherapeutics (LKFT) has a market cap of €1.5B as of May 12, 2026.
What is the P/E ratio for Lakefront Biotherapeutics stock?
The price to earnings (P/E) ratio for Lakefront Biotherapeutics (LKFT) stock is 3.16 as of May 12, 2026.
Does Lakefront Biotherapeutics stock pay dividends?
No, Lakefront Biotherapeutics (LKFT) stock does not pay dividends to its shareholders as of May 12, 2026.
When is the next Lakefront Biotherapeutics dividend payment date?
Lakefront Biotherapeutics (LKFT) stock does not pay dividends to its shareholders.
What is the beta indicator for Lakefront Biotherapeutics?
Lakefront Biotherapeutics (LKFT) does not currently have a Beta indicator.